Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 9/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378073 | 1.00 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL2140 | 1.00 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL3473572 | 0.91 | FFAR1 (0.46) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL3473577 | 0.91 | FFAR1 (0.46) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL2441623 | 0.90 | AGTR1 (0.47) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL2032 | 0.90 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL29561367 | 0.90 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL1808771 | 0.90 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL2033 | 0.90 | AGTR1 (0.66) | AGTR1LTB4R2ABCB11GP6FFAR1 | |
| SCHEMBL1810055 | 0.89 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238761-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-2493848-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051213-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| EP-2316821-A1 | Process for the manufacture of organic compounds | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20070093542-A1 | Process for the preparation of valsartan and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093542-A1 | Process for the preparation of valsartan and intermediates thereof | REN, AGT, ACE | AGTR1 17/4885LTB4R2 1583/4885ABCB11 1225/4885 |
| US-20120238761-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | AGTR1, AGTR2, AGT | AGTR1 1/4885LTB4R2 171/4885ABCB11 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.